Amylin acts rapidly in the brain to induce satiation and reduce meal size, with newer long-acting amylin drugs — especially combined with GLP-1 agonists — showing major promise for obesity treatment.
Reduces binge eating episodesIn human studies, amylin receptor agonists specifically reduced binge eating episodes — beyond just reducing overall caloric intake
What the researchers found
Amylin's primary eating-related effect is rapid, short-lasting satiation that controls meal size, directly reflecting meal-induced rises in circulating amylin. This effect is mediated by humoral (blood-borne) action in the central nervous system, with the area postrema in the caudal hindbrain being the key target region. Amylin also reduces food reward, specifically reducing high-fat food intake in certain conditions. In humans, amylin receptor agonists have reduced binge eating episodes. Long-acting amylin receptor agonists combined with GLP-1 receptor agonists (particularly semaglutide) have emerged as highly promising obesity therapeutics.
Why it matters
The combination of amylin and GLP-1 agonists (like cagrilintide plus semaglutide, marketed as CagriSema) is one of the most anticipated obesity drug combinations in development. Understanding how amylin controls eating through different mechanisms than GLP-1 helps explain why combining them produces greater weight loss than either alone.
How the study worked
This is a narrative review summarizing the key literature on amylin's effects on eating behavior, including its mechanisms of action, brain targets, effects on food reward and binge eating, and the therapeutic potential of long-acting amylin receptor agonists alone and in combination therapy.
What this study cannot tell us
As a review, this paper does not present new data. Much of the foundational research on amylin's eating effects comes from animal models. The review focuses primarily on satiation and food reward effects, not addressing amylin's other metabolic roles. Specific clinical trial results for newer amylin agonists and combination therapies are referenced but not detailed.
How to read the evidence
This is a narrative review by a leading amylin researcher, synthesizing decades of basic and clinical research. It provides authoritative overview but no new experimental data.
When this study was published
Published in 2025, this review captures the most current understanding of amylin biology at a pivotal moment — just as amylin-GLP-1 combination drugs are advancing through late-stage clinical trials.
The bigger picture
Amylin represents a complementary pathway to GLP-1 for appetite control. While GLP-1 drugs have dominated obesity treatment, the next wave of weight loss drugs combines amylin with GLP-1 agonists. CagriSema (cagrilintide + semaglutide) from Novo Nordisk is in phase 3 trials with impressive weight loss results, making amylin biology suddenly very relevant.
Questions still open
- Why does amylin specifically reduce high-fat food preference, and could this be leveraged therapeutically for binge eating disorder?
- How much additional weight loss does adding amylin agonism to GLP-1 therapy provide compared to GLP-1 alone?
- Could amylin's rapid satiation mechanism help address the 'food noise' phenomenon reported by GLP-1 drug users?
Common questions
What is amylin and how does it reduce appetite?
Why is amylin being combined with GLP-1 drugs for obesity?
Read the original research
Role of amylin in feeding and satiation.
Neuropharmacology, 278, 110587
Citation
Lutz, Thomas A. (2025). Role of amylin in feeding and satiation.. Neuropharmacology, 278, 110587. https://doi.org/10.1016/j.neuropharm.2025.110587